Skip to main content
PMC home page
Genitourinary Medicine logoLink to Genitourinary Medicine
. 1997 Feb;73(1):5–11. doi: 10.1136/sti.73.1.5

Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2.

R Heylen 1, R Miller 1
PMCID: PMC1195751  PMID: 9155547

Full text

PDF
9

Images in this article

6Image
on p.6

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carpenter C. C., Fischl M. A., Hammer S. M., Hirsch M. S., Jacobsen D. M., Katzenstein D. A., Montaner J. S., Richman D. D., Sáag M. S., Schooley R. T. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996 Jul 10;276(2):146–154. [PubMed] [Google Scholar]
  2. Collier A. C., Coombs R. W., Schoenfeld D. A., Bassett R. L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V. J. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996 Apr 18;334(16):1011–1017. doi: 10.1056/NEJM199604183341602. [DOI] [PubMed] [Google Scholar]
  3. Condra J. H., Schleif W. A., Blahy O. M., Gabryelski L. J., Graham D. J., Quintero J. C., Rhodes A., Robbins H. L., Roth E., Shivaprakash M. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995 Apr 6;374(6522):569–571. doi: 10.1038/374569a0. [DOI] [PubMed] [Google Scholar]
  4. Danner S. A., Carr A., Leonard J. M., Lehman L. M., Gudiol F., Gonzales J., Raventos A., Rubio R., Bouza E., Pintado V. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995 Dec 7;333(23):1528–1533. doi: 10.1056/NEJM199512073332303. [DOI] [PubMed] [Google Scholar]
  5. Dienstag J. L., Perrillo R. P., Schiff E. R., Bartholomew M., Vicary C., Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995 Dec 21;333(25):1657–1661. doi: 10.1056/NEJM199512213332501. [DOI] [PubMed] [Google Scholar]
  6. Duong M., Sgro C., Grappin M., Biron F., Boibieux A. Renal failure after treatment with ritonavir. Lancet. 1996 Sep 7;348(9028):693–693. doi: 10.1016/S0140-6736(05)65125-2. [DOI] [PubMed] [Google Scholar]
  7. Eron J. J., Benoit S. L., Jemsek J., MacArthur R. D., Santana J., Quinn J. B., Kuritzkes D. R., Fallon M. A., Rubin M. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med. 1995 Dec 21;333(25):1662–1669. doi: 10.1056/NEJM199512213332502. [DOI] [PubMed] [Google Scholar]
  8. Katlama C., Ingrand D., Loveday C., Clumeck N., Mallolas J., Staszewski S., Johnson M., Hill A. M., Pearce G., McDade H. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA. 1996 Jul 10;276(2):118–125. [PubMed] [Google Scholar]
  9. Staszewski S., Loveday C., Picazo J. J., Dellarnonica P., Skinhøj P., Johnson M. A., Danner S. A., Harrigan P. R., Hill A. M., Verity L. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA. 1996 Jul 10;276(2):111–117. [PubMed] [Google Scholar]
  10. van Leeuwen R., Lange J. M., Hussey E. K., Donn K. H., Hall S. T., Harker A. J., Jonker P., Danner S. A. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS. 1992 Dec;6(12):1471–1475. doi: 10.1097/00002030-199212000-00008. [DOI] [PubMed] [Google Scholar]

Articles from Genitourinary Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES